A phase 2 study of sorafenib combined with conventional therapies in refractory central nervous system leukemia.

Xiaoxia ChenJunwei HuangNa XuZhiping FanDanian NieFen HuangQixin SunXinyou ZhangXinquan LiangPengcheng ShiZhixiang WangHui LiuJun XuMin DaiGuo-Pan YuYu ZhangJing SunQi-Fa Liu Li Xuan

Published in: Cancer (2022)

Sorafenib combined with conventional therapies is effective and safe for refractory central nervous system leukemia.

Keyphrases

acute myeloid leukemia
bone marrow
cerebrospinal fluid
open label
randomized controlled trial
double blind